CClinicalTrials.gg
Active, not recruitingNCT06749522Updated Dec 27, 2024

Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis

An observational study in Fibrosis and Cirrhosis, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Superior University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. The incidence and prevalence of disease vary with time. Fibrosis is thickening of connective tissues which is usually as a result of injury and long term inflammation. Cirrhosis is severe scarring of liver which is caused by long term liver damage. The scar tissue replaces healthy tissues which leads to loss of liver function. The Objective of study is to look into radiographic features of fatty liver disease. The high resolution ultrasonography will give more detailed view of disease. The study inclued 150 participants.

Read the detailed description

The other liver conditions like fibrosis and cirrhosis are also examined and correlated with fatty liver disease. The CT and MRI are used to compare with HR ultrasonographic findings. Descriptive statistics and comparative statistics are used to interpret data.

02

Conditions studied

03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's enrollment of 150 is close to the median of 151 across 587 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Superior University is the lead sponsor of 242 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

to compare the Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography (CT, MRI) Of Fibrosis And Cirrhosis

Inclusion criteria

  • Confirmed diagnosis of fatty liver (steatosis), fibrosis, or cirrhosis.
  • Patient consent to undergo imaging and participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Other Liver Diseases: Exclusion of patients with other significant liver conditions (e.g., viral hepatitis, autoimmune liver diseases) unless specified.
  • Pregnant women may be excluded due to imaging concerns.
  • Poor quality or incomplete imaging studies.
  • Presence of other severe systemic illnesses that could affect liver function or imaging.
  • Recent liver surgeries or invasive procedures that might affect imaging results
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No

Interventions

  • Radiationhigh resolution ultrasonography

    to compare high resolution ultrasonography finings with other imaging modalities(CT and MRI)

06

What researchers measure

Primary outcomes

  1. CT

    CT used for the image comparision

    Time frame: 12 Months

  2. MRI

    CT used for the image comparision

    Time frame: 12 Months

07

Study locations

1 site
  • AL-NAWAZ HOSPITAL,Tillu Road
    Sādiqābād, Punjab, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06749522
Lead sponsor
Superior University
Responsible party
Muhammad Naveed Babur (Principal Investigator, Superior University) — Principal investigator
First posted
Dec 27, 2024
Start date
Feb 28, 2024
Primary completion
Jul 1, 2024
Completion
Mar 1, 2025 (estimated)
Last update
Dec 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion